Methods of Diagnosing and Treating Cancer in Patients Having or Developing Resistance to a First Cancer Therapy

a cancer therapy and cancer patient technology, applied in the field of cancer patients having or developing resistance to a first cancer therapy, can solve the problems that the clinical response to targeted anticancer therapy is often confused by de novo or acquired resistance, and achieve the effect of effective long-term treatment strategy
US20130059851A1Inactive Publication Date: 2013-03-07THE BROAD INST INC +1
2 Cites 10 Cited by

Patent Information

Authority / Receiving Office
US · United States
Patent Type
Applications(United States)
Current Assignee / Owner
THE BROAD INST INC
Publication Date
2013-03-07
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

A method of identifying a subject having cancer who is likely to benefit from treatment with a combination therapy with a RAF inhibitor and a second inhibitor is provided. A method of treating cancer in a subject in need thereof is also provided and includes administering to the subject an effective amount of a RAF inhibitor and an effective amount of a second inhibitor, wherein the second inhibitor is a MEK inhibitor, a CRAF inhibitor, a CrkL inhibitor or a TPL2 / COT inhibitor. A method of identifying a kinase target that confers resistance to a first inhibitor is also provided.
Need to check novelty before this filing date? Find Prior Art

Description

RELATED APPLICATIONS

[0001] This application claims the benefit of the filing date under 35 U.S.C. §119(e) of the following Provisional U.S. Patent Application Serial Nos. 61 / 312,193, filed Mar. 9, 2010; 61 / 312,519, filed Mar. 10, 2010; 61 / 326,021, filed Apr. 20, 2010; and 61 / 415,569, filed Nov. 19, 2010, all of which are hereby incorporated by reference in their entirety.FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT

[0002] This invention was made with government support under federal grant numbers K08 CA115927 and 1DP20D002750 awarded by National Institutes of Health. The government has certain rights in the invention.BACKGROUND

[0003] Oncogenic mutations in the serine / threonine kinase B-RAF (also known as BRAF) are found in 50-70% of malignant melanomas. (Davies, H. et al., Nature 417, 949-954 (2002).) Pre-clinical studies have demonstrated that the B-RAF(V600E) mutation predicts a dependency on the mitogen-activated protein kinase (MAPK) signalling cascade in melanoma (Hoeflich, K. P. et...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More